https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic-treatment-of-hae 2024-11-04T23:11:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic-treatment-of-hae 2024-11-04T23:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/dupilumab-reduces-itch-in-chronic-spontaneous-urticaria-in-phase-3-data-hcplive 2024-11-04T23:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupilumab-reduces-itch-in-chronic-spontaneous-urticaria-in-phase-3-data-hcplive 2024-11-04T23:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-a-kind-case-study-shows-remarkable-improvements-for-prostate-cancer-patient 2024-11-04T23:01:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-of-a-kind-case-study-shows-remarkable-improvements-for-prostate-cancer-patient 2024-11-04T23:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-longview-news-journal 2024-11-04T22:54:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-longview-news-journal 2024-11-04T22:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/another-arrow-to-the-quiver-for-physicians-fda-approves-emrosi-for-rosacea-healio 2024-11-04T22:48:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/another-arrow-to-the-quiver-for-physicians-fda-approves-emrosi-for-rosacea-healio 2024-11-04T22:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/adverum-biotechnologies-inc-sec-10-q-report-tradingview 2024-11-04T22:31:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adverum-biotechnologies-inc-sec-10-q-report-tradingview 2024-11-04T22:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-introduces-pr-newswire 2024-11-04T22:25:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-introduces-pr-newswire 2024-11-04T22:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T22:02:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T22:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-director-steven-chaouki-buys-55553-in-shares-investing-com 2024-11-04T22:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-director-steven-chaouki-buys-55553-in-shares-investing-com 2024-11-04T22:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-director-luput-acquires-shares-worth-55553-investing-com 2024-11-04T21:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-director-luput-acquires-shares-worth-55553-investing-com 2024-11-04T21:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/aquestive-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T21:48:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aquestive-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T21:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-reports-third-quarter-2024-globenewswire 2024-11-04T21:39:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unity-biotechnology-inc-reports-third-quarter-2024-globenewswire 2024-11-04T21:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:34:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-04T21:16:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-04T21:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-option-for-rosacea-medpage-today 2024-11-04T21:15:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-option-for-rosacea-medpage-today 2024-11-04T21:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-breakthrough-therapy-designation-shows-38-7-approval-rate-with-317-products-receiving-market-authorization 2024-11-04T21:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-breakthrough-therapy-designation-shows-38-7-approval-rate-with-317-products-receiving-market-authorization 2024-11-04T21:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/neuropace-announces-fda-submission-of-three-year-data-from-globenewswire 2024-11-04T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuropace-announces-fda-submission-of-three-year-data-from-globenewswire 2024-11-04T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/novel-gene-therapy-for-neovascular-age-related-macular-degeneration-medpage-today 2024-11-04T21:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-gene-therapy-for-neovascular-age-related-macular-degeneration-medpage-today 2024-11-04T21:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/lsd-the-bad-and-potentially-good-sides-psychology-today 2024-11-04T20:57:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lsd-the-bad-and-potentially-good-sides-psychology-today 2024-11-04T20:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/letter-warns-clinicians-of-severe-infections-with-pralsetinib-for-nsclc 2024-11-04T20:37:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/letter-warns-clinicians-of-severe-infections-with-pralsetinib-for-nsclc 2024-11-04T20:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-found-gold-pulls-high-grade-gold-out-of-queensway-project-in-newfoundland 2024-11-04T20:28:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-found-gold-pulls-high-grade-gold-out-of-queensway-project-in-newfoundland 2024-11-04T20:28:42+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-of-tavneos-enrolling-children-ages-6-17-with-aav-anca-vasculitis-news 2024-11-04T20:25:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-of-tavneos-enrolling-children-ages-6-17-with-aav-anca-vasculitis-news 2024-11-04T20:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/a-crazy-idea-for-treating-autoimmune-diseases-might-actually-work-the-atlantic 2024-11-04T20:13:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-crazy-idea-for-treating-autoimmune-diseases-might-actually-work-the-atlantic 2024-11-04T20:13:01+00:00 weekly 0.7 https://trial.medpath.com/news/disc-teases-potential-nda-for-rare-skin-disorder-drug-clinical-trials-arena 2024-11-04T20:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disc-teases-potential-nda-for-rare-skin-disorder-drug-clinical-trials-arena 2024-11-04T20:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-globenewswire 2024-11-04T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-globenewswire 2024-11-04T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/shockwave-medical-s-javelin-ivl-catheter-meets-primary-trial-endpoints-massdevice 2024-11-04T19:54:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shockwave-medical-s-javelin-ivl-catheter-meets-primary-trial-endpoints-massdevice 2024-11-04T19:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T19:44:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T19:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-ide-application-for-katana-thrombectomy-system-venous-news 2024-11-04T19:40:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-ide-application-for-katana-thrombectomy-system-venous-news 2024-11-04T19:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/roflumilast-reduces-disease-impact-of-atopic-dermatitis-hcplive 2024-11-04T19:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roflumilast-reduces-disease-impact-of-atopic-dermatitis-hcplive 2024-11-04T19:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-globenewswire 2024-11-04T19:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-globenewswire 2024-11-04T19:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/enhancing-diversity-and-accessibility-in-clinical-trials-for-alzheimer-disease-neurologylive 2024-11-04T19:04:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhancing-diversity-and-accessibility-in-clinical-trials-for-alzheimer-disease-neurologylive 2024-11-04T19:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/the-state-of-the-art-of-n-of-1-therapies-and-the-irdirc-n-of-1-development-roadmap 2024-11-04T18:58:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-state-of-the-art-of-n-of-1-therapies-and-the-irdirc-n-of-1-development-roadmap 2024-11-04T18:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/unexpected-immunotherapy-success-in-rare-pancreatic-cancer-news-medical 2024-11-04T18:40:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unexpected-immunotherapy-success-in-rare-pancreatic-cancer-news-medical 2024-11-04T18:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-forges-new-standard-of-care-for-advanced-hodgkin-lymphoma-inventum 2024-11-04T18:23:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-forges-new-standard-of-care-for-advanced-hodgkin-lymphoma-inventum 2024-11-04T18:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/new-funding-drives-a-slew-of-breast-cancer-studies-fred-hutchinson-cancer-center 2024-11-04T18:18:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-funding-drives-a-slew-of-breast-cancer-studies-fred-hutchinson-cancer-center 2024-11-04T18:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-2-4-mg-shows-superior-improvement-in-liver-fibrosis-mash-resolution-in 2024-11-04T18:15:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-2-4-mg-shows-superior-improvement-in-liver-fibrosis-mash-resolution-in 2024-11-04T18:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-announces-u-s-fda-approval-of-emrositm-minocycline 2024-11-04T18:13:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-corporation-announces-u-s-fda-approval-of-emrositm-minocycline 2024-11-04T18:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase 2024-11-04T18:11:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase 2024-11-04T18:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-donidalorsen-nda-for-prophylactic-hereditary-angioedema 2024-11-04T18:11:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-donidalorsen-nda-for-prophylactic-hereditary-angioedema 2024-11-04T18:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/urticaria-clinical-trial-pipeline-accelerates-20-leading-globenewswire 2024-11-04T18:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urticaria-clinical-trial-pipeline-accelerates-20-leading-globenewswire 2024-11-04T18:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-validation-of-an-ai-based-pathology-tool-for-scoring-of-metabolic-dysfunction 2024-11-04T18:00:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-validation-of-an-ai-based-pathology-tool-for-scoring-of-metabolic-dysfunction 2024-11-04T18:00:49+00:00 weekly 0.7 https://trial.medpath.com/news/deferiprone-in-alzheimer-disease-a-randomized-clinical-trial-jama-network 2024-11-04T17:58:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deferiprone-in-alzheimer-disease-a-randomized-clinical-trial-jama-network 2024-11-04T17:58:25+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-semaglutide-scores-in-liver-fibrosis-and-mash-trial-inside-precision-medicine 2024-11-04T17:56:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-s-semaglutide-scores-in-liver-fibrosis-and-mash-trial-inside-precision-medicine 2024-11-04T17:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase-iii 2024-11-04T17:52:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase-iii 2024-11-04T17:52:53+00:00 weekly 0.7 https://trial.medpath.com/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-globenewswire 2024-11-04T17:44:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-globenewswire 2024-11-04T17:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T17:43:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T17:43:20+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-fda-green-light-for-phase-ii-study-marketscreener 2024-11-04T17:40:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-fda-green-light-for-phase-ii-study-marketscreener 2024-11-04T17:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T17:39:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T17:39:03+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T17:34:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T17:34:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant-yahoo 2024-11-04T17:24:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant-yahoo 2024-11-04T17:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/teva-s-long-lasting-schizophrenia-injectable-shines-in-phase-iii-clinical-trials-arena 2024-11-04T17:24:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-s-long-lasting-schizophrenia-injectable-shines-in-phase-iii-clinical-trials-arena 2024-11-04T17:24:08+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-planning-phase-3-trials-of-denifanstat-in-mash-masld-liver-disease-news 2024-11-04T17:20:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-planning-phase-3-trials-of-denifanstat-in-mash-masld-liver-disease-news 2024-11-04T17:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/ela026-receives-orphan-drug-designation-to-treat-hemophagocytic-lymphohistiocytosis 2024-11-04T17:19:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ela026-receives-orphan-drug-designation-to-treat-hemophagocytic-lymphohistiocytosis 2024-11-04T17:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:03:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/r3-vascular-wins-fda-ide-for-drug-eluting-scaffold-massdevice 2024-11-04T16:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/r3-vascular-wins-fda-ide-for-drug-eluting-scaffold-massdevice 2024-11-04T16:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-hailed-as-major-breakthrough-could-actually-triple-risk-of-dying-ucl-news 2024-11-04T16:48:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-hailed-as-major-breakthrough-could-actually-triple-risk-of-dying-ucl-news 2024-11-04T16:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-shares-rise-on-strong-phase-3-prospects-gets-buy-rating-investing-com 2024-11-04T16:41:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polypid-shares-rise-on-strong-phase-3-prospects-gets-buy-rating-investing-com 2024-11-04T16:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-combination-may-demonstrate-benefit-in-patients-with-cutaneous-melanoma 2024-11-04T16:34:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-combination-may-demonstrate-benefit-in-patients-with-cutaneous-melanoma 2024-11-04T16:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/results-of-elevatim-show-improvement-in-diabetic-macular-edema-with-vabysmo-for 2024-11-04T16:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/results-of-elevatim-show-improvement-in-diabetic-macular-edema-with-vabysmo-for 2024-11-04T16:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-presents-positive-data-from-vk2735-for-reducing-body-weight 2024-11-04T16:23:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viking-therapeutics-presents-positive-data-from-vk2735-for-reducing-body-weight 2024-11-04T16:23:57+00:00 weekly 0.7 https://trial.medpath.com/news/valemetostat-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-the-asco-post 2024-11-04T16:20:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valemetostat-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-the-asco-post 2024-11-04T16:20:17+00:00 weekly 0.7 https://trial.medpath.com/news/lasofoxifene-suppresses-ki-67-expression-in-hr-her2-early-stage-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lasofoxifene-suppresses-ki-67-expression-in-hr-her2-early-stage-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-shr-a1811-plus-pyrotinib-shows-preliminary-efficacy-safety-in-her2-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-shr-a1811-plus-pyrotinib-shows-preliminary-efficacy-safety-in-her2-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/bxq-350-is-well-tolerated-shows-clinical-activity-in-advanced-solid-tumors-onclive 2024-11-04T16:19:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bxq-350-is-well-tolerated-shows-clinical-activity-in-advanced-solid-tumors-onclive 2024-11-04T16:19:48+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-begins-trial-of-acute-myeloid-leukaemia-treatment-in-children 2024-11-04T16:11:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-begins-trial-of-acute-myeloid-leukaemia-treatment-in-children 2024-11-04T16:11:32+00:00 weekly 0.7 https://trial.medpath.com/news/key-fda-decisions-made-in-2024-news-medical 2024-11-04T16:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-fda-decisions-made-in-2024-news-medical 2024-11-04T16:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-quanta-home-hemodialysis-system-massdevice 2024-11-04T16:09:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-quanta-home-hemodialysis-system-massdevice 2024-11-04T16:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/radiprodil-in-tsc-and-fcd-targeting-seizures-through-nmda-modulation-neurologylive 2024-11-04T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiprodil-in-tsc-and-fcd-targeting-seizures-through-nmda-modulation-neurologylive 2024-11-04T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-may-outperform-standard-care-for-relapsed-refractory-myeloma 2024-11-04T16:06:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilta-cel-may-outperform-standard-care-for-relapsed-refractory-myeloma 2024-11-04T16:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/first-patients-dosed-in-new-phase-3-trials-of-dato-dxd-in-nsclc-targeted-oncology 2024-11-04T16:01:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patients-dosed-in-new-phase-3-trials-of-dato-dxd-in-nsclc-targeted-oncology 2024-11-04T16:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/clofutriben-receives-fda-orphan-drug-designation-to-treat-endogenous-cushing-syndrome 2024-11-04T15:51:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clofutriben-receives-fda-orphan-drug-designation-to-treat-endogenous-cushing-syndrome 2024-11-04T15:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/ventus-therapeutics-announces-positive-phase-1-trial-results-for-investigational-drug 2024-11-04T15:44:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ventus-therapeutics-announces-positive-phase-1-trial-results-for-investigational-drug 2024-11-04T15:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/raymond-james-increases-disc-medicine-shares-to-strong-buy-on-new-drug-investing-com 2024-11-04T15:42:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/raymond-james-increases-disc-medicine-shares-to-strong-buy-on-new-drug-investing-com 2024-11-04T15:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-weight-loss-pill-outperforms-ozempic-marker-novo-nordisk-s-quartz 2024-11-04T15:41:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viking-therapeutics-weight-loss-pill-outperforms-ozempic-marker-novo-nordisk-s-quartz 2024-11-04T15:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug 2024-11-04T15:39:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug 2024-11-04T15:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/new-guselkumab-data-indicate-robust-effectiveness-in-crohn-disease-plaque-psoriasis 2024-11-04T15:34:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-guselkumab-data-indicate-robust-effectiveness-in-crohn-disease-plaque-psoriasis 2024-11-04T15:34:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-dfd-29-for-rosacea-dermatology-times 2024-11-04T15:24:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-journey-medical-s-dfd-29-for-rosacea-dermatology-times 2024-11-04T15:24:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-holds-placed-on-3-car-t-cell-therapy-trials-targeted-oncology 2024-11-04T15:21:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-clinical-holds-placed-on-3-car-t-cell-therapy-trials-targeted-oncology 2024-11-04T15:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-approval-to-commence-trial-of-r3-vascular-s-scaffold-medical-device-network 2024-11-04T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-approval-to-commence-trial-of-r3-vascular-s-scaffold-medical-device-network 2024-11-04T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/news/implant-could-prevent-opioid-overdose-deaths-news-center 2024-11-04T15:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implant-could-prevent-opioid-overdose-deaths-news-center 2024-11-04T15:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/saint-itbs-protocol-shows-promise-for-bipolar-i-depression-psychiatric-times 2024-11-04T15:04:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/saint-itbs-protocol-shows-promise-for-bipolar-i-depression-psychiatric-times 2024-11-04T15:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:58:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-disease-therapy-current-strategies-and-future-research-priorities-nature 2024-11-04T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-disease-therapy-current-strategies-and-future-research-priorities-nature 2024-11-04T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:56:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:51:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/small-molecules-sustaining-big-pharma-a-look-at-some-recent-headlines-the-medicine-maker 2024-11-04T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/small-molecules-sustaining-big-pharma-a-look-at-some-recent-headlines-the-medicine-maker 2024-11-04T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:41:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-04T14:36:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-04T14:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/dosing-begins-in-early-clinical-trial-of-lucid-ms-to-protect-myelin-sheath 2024-11-04T14:36:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dosing-begins-in-early-clinical-trial-of-lucid-ms-to-protect-myelin-sheath 2024-11-04T14:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-shines-with-promising-results-for-new-obesity-drug-finimize 2024-11-04T14:34:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viking-therapeutics-shines-with-promising-results-for-new-obesity-drug-finimize 2024-11-04T14:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/prehabilitative-rehabilitative-exercise-nutrition-and-psychological-support-for-bladder-cancer 2024-11-04T14:27:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prehabilitative-rehabilitative-exercise-nutrition-and-psychological-support-for-bladder-cancer 2024-11-04T14:27:11+00:00 weekly 0.7 https://trial.medpath.com/news/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:25:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:25:27+00:00 weekly 0.7 https://trial.medpath.com/news/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:22:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/che-negatively-impacts-quality-of-life-according-to-patients-dermatology-times 2024-11-04T14:09:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/che-negatively-impacts-quality-of-life-according-to-patients-dermatology-times 2024-11-04T14:09:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-minocycline-hydrochloride-extended-release-capsules-for-individuals-with-rosacea 2024-11-04T14:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-minocycline-hydrochloride-extended-release-capsules-for-individuals-with-rosacea 2024-11-04T14:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-nation-world 2024-11-04T13:54:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-nation-world 2024-11-04T13:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/cvrx-earns-medicare-win-for-barostim-procedure-massdevice 2024-11-04T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cvrx-earns-medicare-win-for-barostim-procedure-massdevice 2024-11-04T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-fda-approves-emrosi-for-treatment-of-inflammatory-lesions-of-rosacea 2024-11-04T13:43:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-fda-approves-emrosi-for-treatment-of-inflammatory-lesions-of-rosacea 2024-11-04T13:43:25+00:00 weekly 0.7 https://trial.medpath.com/news/krystal-biotech-inc-sec-10-q-report-tradingview 2024-11-04T13:41:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/krystal-biotech-inc-sec-10-q-report-tradingview 2024-11-04T13:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/regorafenib-shows-survival-benefit-in-late-stage-gastric-cancer-integrate-iia-trial 2024-11-04T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regorafenib-shows-survival-benefit-in-late-stage-gastric-cancer-integrate-iia-trial 2024-11-04T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-downgraded-by-oppenheimer-piper-sandler-after-drug-setback-in-trials 2024-11-04T13:23:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-pharma-downgraded-by-oppenheimer-piper-sandler-after-drug-setback-in-trials 2024-11-04T13:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-october-tigris-trial-update-financial-post 2024-11-04T13:20:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-october-tigris-trial-update-financial-post 2024-11-04T13:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:14:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-04T13:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-approves-cstone-pharmaceuticals-sugemalimab-to-treat-lung-cancer-in-adults 2024-11-04T13:12:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-approves-cstone-pharmaceuticals-sugemalimab-to-treat-lung-cancer-in-adults 2024-11-04T13:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-shares-final-long-term-results-for-atopic-dermatitis-drug-adbry-pmlive 2024-11-04T13:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leo-pharma-shares-final-long-term-results-for-atopic-dermatitis-drug-adbry-pmlive 2024-11-04T13:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/patients-achieve-insulin-freedom-with-tegoprubart-immunotherapy 2024-11-04T13:11:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patients-achieve-insulin-freedom-with-tegoprubart-immunotherapy 2024-11-04T13:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/key-trials-on-parp-inhibitor-combinations-in-metastatic-prostate-cancer-urology-times 2024-11-04T13:06:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-trials-on-parp-inhibitor-combinations-in-metastatic-prostate-cancer-urology-times 2024-11-04T13:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-long-term-efficacy-safety-of-stapokibart-for-atopic-dermatitis 2024-11-04T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-data-shows-long-term-efficacy-safety-of-stapokibart-for-atopic-dermatitis 2024-11-04T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-globenewswire 2024-11-04T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-announces-key-takeaways-from-oral-presentations-at-globenewswire 2024-11-04T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T13:02:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T13:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/neurobo-pharmaceuticals-completes-last-patient-last-visit-in-its-phase-2a-clinical-trial 2024-11-04T13:02:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurobo-pharmaceuticals-completes-last-patient-last-visit-in-its-phase-2a-clinical-trial 2024-11-04T13:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T13:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T13:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/teva-s-tev-749-yields-positive-results-in-phase-3-schizophrenia-trial 2024-11-04T12:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-s-tev-749-yields-positive-results-in-phase-3-schizophrenia-trial 2024-11-04T12:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-announces-successful-end-of-phase-2-meeting-globenewswire 2024-11-04T12:53:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disc-medicine-announces-successful-end-of-phase-2-meeting-globenewswire 2024-11-04T12:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/angitia-biopharmaceuticals-announces-dosing-of-first-globenewswire 2024-11-04T12:47:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/angitia-biopharmaceuticals-announces-dosing-of-first-globenewswire 2024-11-04T12:47:17+00:00 weekly 0.7 https://trial.medpath.com/news/record-monthly-enrollment-achieved-in-seastar-medical-s-pivotal-adult-aki-trial-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/record-monthly-enrollment-achieved-in-seastar-medical-s-pivotal-adult-aki-trial-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-biospace 2024-11-04T12:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-reports-third-quarter-2024-financial-results-and-provides 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-inc-reports-third-quarter-2024-financial-results-and-provides 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T12:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-announces-u-s-fda-approval-of-emrositm-minocycline-hydrochloride 2024-11-04T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-announces-u-s-fda-approval-of-emrositm-minocycline-hydrochloride 2024-11-04T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T12:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential 2024-11-04T12:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-announces-third-quarter-2024-financial-results-and-corporate-update 2024-11-04T12:29:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-announces-third-quarter-2024-financial-results-and-corporate-update 2024-11-04T12:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-research-agreement-with-kenya-medical-morningstar 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-announces-research-agreement-with-kenya-medical-morningstar 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/cytosorbents-submits-health-canada-medical-device-license-application-for-drugsorb 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytosorbents-submits-health-canada-medical-device-license-application-for-drugsorb 2024-11-04T12:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-to-study-highly-innovative-single-device 2024-11-04T12:18:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philips-enrolls-first-patient-in-u-s-clinical-trial-to-study-highly-innovative-single-device 2024-11-04T12:18:38+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-anti-obesity-drug-namodenoson-received-patent-allowance-in-australia 2024-11-04T12:11:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-fite-anti-obesity-drug-namodenoson-received-patent-allowance-in-australia 2024-11-04T12:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/dri-healthcare-trust-announces-acquisition-of-a-synthetic-royalty-interest-in-the-markets-data 2024-11-04T12:09:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dri-healthcare-trust-announces-acquisition-of-a-synthetic-royalty-interest-in-the-markets-data 2024-11-04T12:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-yahoo-finance 2024-11-04T12:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-11-04T12:04:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-11-04T12:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/atossa-therapeutics-reports-positive-karisma-endoxifen-trial-results-globenewswire 2024-11-04T11:41:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atossa-therapeutics-reports-positive-karisma-endoxifen-trial-results-globenewswire 2024-11-04T11:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T11:21:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T11:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T11:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T11:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/formosa-pharmaceuticals-announces-successful-top-line-results-from-cpn-303-a-phase 2024-11-04T11:01:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-announces-successful-top-line-results-from-cpn-303-a-phase 2024-11-04T11:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-reports-positive-data-from-part-one-of-semaglutide-trial-for-mash 2024-11-04T10:40:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-reports-positive-data-from-part-one-of-semaglutide-trial-for-mash 2024-11-04T10:40:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant 2024-11-04T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant 2024-11-04T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-fosun-pharma-announces-drug-registration-acceptance-tipranks-com 2024-11-04T10:19:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shanghai-fosun-pharma-announces-drug-registration-acceptance-tipranks-com 2024-11-04T10:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/korean-dementia-association-leqembi-s-side-effects-are-not-significant-komedidaskeom 2024-11-04T09:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/korean-dementia-association-leqembi-s-side-effects-are-not-significant-komedidaskeom 2024-11-04T09:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/grand-pharmaceutical-s-breakthrough-in-ophthalmic-drug-trial-tipranks-com 2024-11-04T09:24:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grand-pharmaceutical-s-breakthrough-in-ophthalmic-drug-trial-tipranks-com 2024-11-04T09:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/shandong-xinhua-pharmaceutical-gains-key-drug-approval-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shandong-xinhua-pharmaceutical-gains-key-drug-approval-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/shandong-xinhua-pharmaceutical-gains-approval-for-pentazocine-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shandong-xinhua-pharmaceutical-gains-approval-for-pentazocine-tipranks-com 2024-11-04T09:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/jongkundang-receives-fda-approval-for-phase-1-clinical-trial-of-new-hyperlipidemia-treatment 2024-11-04T09:13:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jongkundang-receives-fda-approval-for-phase-1-clinical-trial-of-new-hyperlipidemia-treatment 2024-11-04T09:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacists-take-leading-role-in-combating-medical-misinformation-through-evidence-based-strategies 2024-11-04T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacists-take-leading-role-in-combating-medical-misinformation-through-evidence-based-strategies 2024-11-04T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/multiscale-mechanistic-model-of-rheumatoid-arthritis-to-enable-decision-making-in-late 2024-11-04T08:30:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multiscale-mechanistic-model-of-rheumatoid-arthritis-to-enable-decision-making-in-late 2024-11-04T08:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-submits-nda-to-us-fda-for-avutometinib-plus-defactinib-to-treat-pharmabiz 2024-11-04T08:29:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-oncology-submits-nda-to-us-fda-for-avutometinib-plus-defactinib-to-treat-pharmabiz 2024-11-04T08:29:22+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-will-file-semaglutide-for-mash-next-year-pharmaphorum 2024-11-04T07:36:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-will-file-semaglutide-for-mash-next-year-pharmaphorum 2024-11-04T07:36:24+00:00 weekly 0.7 https://trial.medpath.com/news/medincell-s-partner-teva-unveils-new-phase-3-positive-results-for-olanzapine-lai-and 2024-11-04T07:28:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medincell-s-partner-teva-unveils-new-phase-3-positive-results-for-olanzapine-lai-and 2024-11-04T07:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:19:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:18:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-04T07:18:01+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-third-quarter-2024-financial-results-globenewswire 2024-11-04T07:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-reports-third-quarter-2024-financial-results-globenewswire 2024-11-04T07:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T07:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T07:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-globenewswire 2024-11-04T06:48:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-of-qiastat-dx-globenewswire 2024-11-04T06:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:48:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:40:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:38:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-of-qiastat-dx-meningitis-encephalitis-panel-to-support 2024-11-04T06:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/prokarium-secures-two-us-patents-for-novel-cancer-immunotherapy-platform 2024-11-04T06:08:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prokarium-secures-two-us-patents-for-novel-cancer-immunotherapy-platform 2024-11-04T06:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/pioneering-gene-therapies-coming-from-zayed-centre-breakthroughs-the-national 2024-11-04T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneering-gene-therapies-coming-from-zayed-centre-breakthroughs-the-national 2024-11-04T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-paradigm-shift-in-cancer-drug-dosing-moving-beyond-maximum-tolerated-dose 2024-11-04T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-paradigm-shift-in-cancer-drug-dosing-moving-beyond-maximum-tolerated-dose 2024-11-04T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytoki-pharma-announces-first-patient-dosed-in-phase-2-study-of-ck-0045-in-obesity-and 2024-11-04T05:32:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytoki-pharma-announces-first-patient-dosed-in-phase-2-study-of-ck-0045-in-obesity-and 2024-11-04T05:32:16+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-to-provide-corporate-update-at-the-spartan-capital-investors-conference 2024-11-04T05:32:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-to-provide-corporate-update-at-the-spartan-capital-investors-conference 2024-11-04T05:32:11+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-medical-advances-in-neurological-drug-development-markets-insider 2024-11-04T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinogen-medical-advances-in-neurological-drug-development-markets-insider 2024-11-04T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-journey-merus-ptc-and-autolus-biospace 2024-11-04T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-journey-merus-ptc-and-autolus-biospace 2024-11-04T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/7-alzheimer-s-and-parkinson-s-programs-discarded-in-2024-biospace 2024-11-04T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7-alzheimer-s-and-parkinson-s-programs-discarded-in-2024-biospace 2024-11-04T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/cipla-share-price-rises-11-in-three-sessions-as-brokerages-positive-on-us-fda-clearance 2024-11-04T04:53:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cipla-share-price-rises-11-in-three-sessions-as-brokerages-positive-on-us-fda-clearance 2024-11-04T04:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/successful-treatment-of-pediatric-generalized-pustular-psoriasis-gpp-dove-medical-press 2024-11-04T04:51:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/successful-treatment-of-pediatric-generalized-pustular-psoriasis-gpp-dove-medical-press 2024-11-04T04:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/court-blocks-sun-pharma-s-alopecia-drug-launch-following-incyte-patent-dispute 2024-11-04T04:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/court-blocks-sun-pharma-s-alopecia-drug-launch-following-incyte-patent-dispute 2024-11-04T04:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/endevica-bio-launches-abisati-to-advance-novel-obesity-drug-710go-into-clinical-trials 2024-11-04T04:12:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endevica-bio-launches-abisati-to-advance-novel-obesity-drug-710go-into-clinical-trials 2024-11-04T04:12:33+00:00 weekly 0.7 https://trial.medpath.com/news/iisc-gets-rs-52-47-crore-under-ayurswasthya-yojna-for-coe-in-ayurveda-for-diabetes-and 2024-11-04T02:30:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iisc-gets-rs-52-47-crore-under-ayurswasthya-yojna-for-coe-in-ayurveda-for-diabetes-and 2024-11-04T02:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-phase-1-dose-escalation-and-dose-expansion-study-of-a-ret-inhibitor-sy-nature 2024-11-04T01:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-phase-1-dose-escalation-and-dose-expansion-study-of-a-ret-inhibitor-sy-nature 2024-11-04T01:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/a-round-up-of-alzheimer-s-drug-trials-news-from-ctad-2024-being-patient 2024-11-04T01:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-round-up-of-alzheimer-s-drug-trials-news-from-ctad-2024-being-patient 2024-11-04T01:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-emrosi-minocycline-hydrochloride-for-the-treatment-of-rosacea 2024-11-04T00:11:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-emrosi-minocycline-hydrochloride-for-the-treatment-of-rosacea 2024-11-04T00:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-corporation-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hanall-biopharma-reports-q3-2024-financial-results-and 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanall-biopharma-reports-q3-2024-financial-results-and 2024-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-digital-health-behavior-intervention-to-prevent-childhood-obesity-jama-network 2024-11-03T22:55:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-digital-health-behavior-intervention-to-prevent-childhood-obesity-jama-network 2024-11-03T22:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-corporate-presentation-november-2024-marketscreener 2024-11-03T21:44:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-corporate-presentation-november-2024-marketscreener 2024-11-03T21:44:33+00:00 weekly 0.7 https://trial.medpath.com/news/unified-clinical-platforms-drive-efficiency-in-drug-development-through-strategic-it-models 2024-11-03T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unified-clinical-platforms-drive-efficiency-in-drug-development-through-strategic-it-models 2024-11-03T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-select-trial-analysis-with-semaglutide-2-4-mg-showed-a-significant-reduction-morningstar 2024-11-03T20:46:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-select-trial-analysis-with-semaglutide-2-4-mg-showed-a-significant-reduction-morningstar 2024-11-03T20:46:31+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-progression-may-be-slowed-by-targeted-magnetic-pulses-study-suggests 2024-11-03T20:46:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-progression-may-be-slowed-by-targeted-magnetic-pulses-study-suggests 2024-11-03T20:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/graphene-chip-implant-in-uk-trial-could-transform-brain-tumour-surgery-the-guardian 2024-11-03T20:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/graphene-chip-implant-in-uk-trial-could-transform-brain-tumour-surgery-the-guardian 2024-11-03T20:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/adjunctive-antipsychotic-helps-ease-symptoms-of-depression-medpage-today 2024-11-03T20:16:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjunctive-antipsychotic-helps-ease-symptoms-of-depression-medpage-today 2024-11-03T20:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/intas-pharmaceutical-gets-cdsco-panels-nod-to-conduct-phase-iii-clinical-trial-of-ruxolitinib-cream 2024-11-03T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intas-pharmaceutical-gets-cdsco-panels-nod-to-conduct-phase-iii-clinical-trial-of-ruxolitinib-cream 2024-11-03T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/leukocytes-telomere-length-as-a-biomarker-of-adverse-drug-reactions-induced-by-nature 2024-11-03T20:03:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leukocytes-telomere-length-as-a-biomarker-of-adverse-drug-reactions-induced-by-nature 2024-11-03T20:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-healthcare-gets-cdsco-panel-nod-to-study-asthma-drug-sar443765 2024-11-03T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-healthcare-gets-cdsco-panel-nod-to-study-asthma-drug-sar443765 2024-11-03T19:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/contributor-the-era-of-disease-modifying-alzheimer-disease-treatments 2024-11-03T19:43:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contributor-the-era-of-disease-modifying-alzheimer-disease-treatments 2024-11-03T19:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/rheumatology-month-in-review-october-2024-hcplive 2024-11-03T19:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rheumatology-month-in-review-october-2024-hcplive 2024-11-03T19:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/marking-a-new-era-in-patient-care-with-advancements-in-disease-modifying-alzheimer-treatments 2024-11-03T19:04:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marking-a-new-era-in-patient-care-with-advancements-in-disease-modifying-alzheimer-treatments 2024-11-03T19:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/nda-filed-for-avutometinib-plus-defactinib-for-low-grade-serous-ovarian-cancer 2024-11-03T18:09:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nda-filed-for-avutometinib-plus-defactinib-for-low-grade-serous-ovarian-cancer 2024-11-03T18:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/cinfina-pharma-presents-positive-phase-1-study-results-in-poster-session-for-cin-109-and 2024-11-03T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinfina-pharma-presents-positive-phase-1-study-results-in-poster-session-for-cin-109-and 2024-11-03T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/flasco-fall-session-advancements-in-mrd-monitoring-using-ctdna-in-lung-cancer 2024-11-03T17:04:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/flasco-fall-session-advancements-in-mrd-monitoring-using-ctdna-in-lung-cancer 2024-11-03T17:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/twice-yearly-lenacapavir-may-change-the-world-if-we-make-it-work-contagion-live 2024-11-03T16:59:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/twice-yearly-lenacapavir-may-change-the-world-if-we-make-it-work-contagion-live 2024-11-03T16:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-03T15:47:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-03T15:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/induction-chemotherapy-combination-boosts-pfs-os-in-cervical-cancer 2024-11-03T15:07:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/induction-chemotherapy-combination-boosts-pfs-os-in-cervical-cancer 2024-11-03T15:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/caroline-diorio-md-frcpc-faap-on-noninflammatory-neurotoxicity-events-in-patients 2024-11-03T14:20:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caroline-diorio-md-frcpc-faap-on-noninflammatory-neurotoxicity-events-in-patients 2024-11-03T14:20:41+00:00 weekly 0.7 https://trial.medpath.com/news/implications-of-findings-on-patient-reported-outcomes-for-roflumilast-foam-with-melinda 2024-11-03T14:01:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implications-of-findings-on-patient-reported-outcomes-for-roflumilast-foam-with-melinda 2024-11-03T14:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/new-psychiatric-technique-asks-schizophrenics-to-engage-in-dialogue-with-the-voices-futurism 2024-11-03T13:54:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-psychiatric-technique-asks-schizophrenics-to-engage-in-dialogue-with-the-voices-futurism 2024-11-03T13:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/why-sun-pharma-may-be-in-focus-on-monday-cnbc-tv18 2024-11-03T13:39:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-sun-pharma-may-be-in-focus-on-monday-cnbc-tv18 2024-11-03T13:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-bilicocoon-phototherapy-with-overhead-phototherapy-in-hyperbilirubinemic 2024-11-03T13:19:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparison-of-bilicocoon-phototherapy-with-overhead-phototherapy-in-hyperbilirubinemic 2024-11-03T13:19:19+00:00 weekly 0.7 https://trial.medpath.com/news/role-of-tumor-specific-and-whole-body-imaging-biomarkers-for-prediction-of-recurrence-in 2024-11-03T13:04:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/role-of-tumor-specific-and-whole-body-imaging-biomarkers-for-prediction-of-recurrence-in 2024-11-03T13:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharmaceuticals-holds-public-offering-to-advance-clinical-trials-defense-world 2024-11-03T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharmaceuticals-holds-public-offering-to-advance-clinical-trials-defense-world 2024-11-03T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-uncover-the-latest-from-wclc-and-experts-insights-into-latest 2024-11-03T12:01:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-uncover-the-latest-from-wclc-and-experts-insights-into-latest 2024-11-03T12:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-takeda-reports-robust-h1-growth-revises-full-year-guidance-investing-com 2024-11-03T11:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-takeda-reports-robust-h1-growth-revises-full-year-guidance-investing-com 2024-11-03T11:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/shr-a1921-demonstrates-early-efficacy-in-platinum-resistant-ovarian-cancer-onclive 2024-11-03T11:09:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shr-a1921-demonstrates-early-efficacy-in-platinum-resistant-ovarian-cancer-onclive 2024-11-03T11:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/the-r-o-a-d-to-precision-medicine-nature 2024-11-03T09:40:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-r-o-a-d-to-precision-medicine-nature 2024-11-03T09:40:29+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-alpha-1-antitrypsin-deficiency-aatd-nct06622668-crispr-medicine 2024-11-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-alpha-1-antitrypsin-deficiency-aatd-nct06622668-crispr-medicine 2024-11-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/16-hospitals-test-potentially-life-saving-device-designed-for-indian-stroke-patients 2024-11-03T09:23:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/16-hospitals-test-potentially-life-saving-device-designed-for-indian-stroke-patients 2024-11-03T09:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/debra-miller-los-angeles-times 2024-11-03T09:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/debra-miller-los-angeles-times 2024-11-03T09:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/novel-anti-mdm2-protac-shows-promise-for-p53-mutated-cancer-treatment 2024-11-03T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-anti-mdm2-protac-shows-promise-for-p53-mutated-cancer-treatment 2024-11-03T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-scientist-who-tested-his-revolutionary-medicine-on-his-own-brain-cancer-the-guardian 2024-11-03T07:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-scientist-who-tested-his-revolutionary-medicine-on-his-own-brain-cancer-the-guardian 2024-11-03T07:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-for-pembrolizumab-in-non-small-cell-lung-cancer-a-nationwide-cohort-study 2024-11-03T07:15:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-for-pembrolizumab-in-non-small-cell-lung-cancer-a-nationwide-cohort-study 2024-11-03T07:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-03T05:06:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-03T05:06:35+00:00 weekly 0.7 https://trial.medpath.com/news/the-european-medicines-agency-approves-the-moderna-vaccine 2024-11-03T03:43:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-european-medicines-agency-approves-the-moderna-vaccine 2024-11-03T03:43:43+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-pharma-sehk-9969-achieves-key-milestone-with-icp-488-phase-ii-success-in 2024-11-03T00:57:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-pharma-sehk-9969-achieves-key-milestone-with-icp-488-phase-ii-success-in 2024-11-03T00:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/mtnb-matinas-biopharma-holdings-inc-latest-stock-news-market-updates 2024-11-03T00:29:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mtnb-matinas-biopharma-holdings-inc-latest-stock-news-market-updates 2024-11-03T00:29:30+00:00 weekly 0.7 https://trial.medpath.com/news/driver-mutations-associated-with-signatures-of-platinum-sensitivity-in-germ-cell-tumors 2024-11-03T00:10:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/driver-mutations-associated-with-signatures-of-platinum-sensitivity-in-germ-cell-tumors 2024-11-03T00:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-shows-promise-for-osteoarthritis-pain-relief-the-pinnacle-gazette 2024-11-02T23:51:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-shows-promise-for-osteoarthritis-pain-relief-the-pinnacle-gazette 2024-11-02T23:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/hospital-tries-car-t-therapy-for-lung-cancer-shine-news-shanghai-daily 2024-11-02T23:28:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hospital-tries-car-t-therapy-for-lung-cancer-shine-news-shanghai-daily 2024-11-02T23:28:57+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-xanomeline-and-trospium-chloride-in-schizophrenia-pooled-results-from-three-5 2024-11-02T23:14:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-xanomeline-and-trospium-chloride-in-schizophrenia-pooled-results-from-three-5 2024-11-02T23:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/merus-annonce-ses-resultats-financiers-pour-le-troisieme-globenewswire 2024-11-02T22:20:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-annonce-ses-resultats-financiers-pour-le-troisieme-globenewswire 2024-11-02T22:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-solid-tumors-nct06598371-crispr-medicine-news 2024-11-02T21:30:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-solid-tumors-nct06598371-crispr-medicine-news 2024-11-02T21:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-hereditary-angioedema-hae-nct06634420-crispr-medicine-news 2024-11-02T21:30:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-hereditary-angioedema-hae-nct06634420-crispr-medicine-news 2024-11-02T21:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/uk-s-nice-says-alzheimer-s-disease-drug-kisunla-is-not-cost-effective-forbes 2024-11-02T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-s-nice-says-alzheimer-s-disease-drug-kisunla-is-not-cost-effective-forbes 2024-11-02T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-precision-medicine-to-psychiatry-circular-rnas-as-a-window-into-the-brain-nature 2024-11-02T19:10:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bringing-precision-medicine-to-psychiatry-circular-rnas-as-a-window-into-the-brain-nature 2024-11-02T19:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/hoping-for-a-weight-loss-pill-it-could-get-closer-to-reality-next-week-morningstar 2024-11-02T18:25:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hoping-for-a-weight-loss-pill-it-could-get-closer-to-reality-next-week-morningstar 2024-11-02T18:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/gastroenterology-month-in-review-october-2024-hcplive 2024-11-02T18:03:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastroenterology-month-in-review-october-2024-hcplive 2024-11-02T18:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/remission-rate-toxicity-and-pharmacokinetics-of-venetoclax-based-induction-regimens-in-nature 2024-11-02T17:45:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remission-rate-toxicity-and-pharmacokinetics-of-venetoclax-based-induction-regimens-in-nature 2024-11-02T17:45:04+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-dosing-of-donanemab-lowers-aria-risk-anti-tau-agent-e2814-shows 2024-11-02T17:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhanced-dosing-of-donanemab-lowers-aria-risk-anti-tau-agent-e2814-shows 2024-11-02T17:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/asco-seeks-to-expand-pharmacist-membership-and-engagement-in-oncology-standards-development 2024-11-02T16:53:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco-seeks-to-expand-pharmacist-membership-and-engagement-in-oncology-standards-development 2024-11-02T16:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-october-26-2024 2024-11-02T16:37:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-in-ophthalmology-week-of-october-26-2024 2024-11-02T16:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-so-effective-at-treating-arthritis-that-patients-were-more-or-less-were-futurism 2024-11-02T16:36:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-so-effective-at-treating-arthritis-that-patients-were-more-or-less-were-futurism 2024-11-02T16:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-policy-monitor-november-12-2024-aacr 2024-11-02T16:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-policy-monitor-november-12-2024-aacr 2024-11-02T16:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-89bio-jump-after-novo-s-semaglutide-shows-promise-in-mash-yahoo-finance 2024-11-02T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-89bio-jump-after-novo-s-semaglutide-shows-promise-in-mash-yahoo-finance 2024-11-02T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/guanxinning-for-residual-inflammation-of-stable-coronary-artery-diseas-dove-medical-press 2024-11-02T15:51:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guanxinning-for-residual-inflammation-of-stable-coronary-artery-diseas-dove-medical-press 2024-11-02T15:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/bath-hospital-needs-volunteers-for-stroke-drug-study-bbc 2024-11-02T15:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bath-hospital-needs-volunteers-for-stroke-drug-study-bbc 2024-11-02T15:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-votes-against-sotagliflozin-for-glucose-control-in-type-1-diabetes-ckd-healio 2024-11-02T14:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-panel-votes-against-sotagliflozin-for-glucose-control-in-type-1-diabetes-ckd-healio 2024-11-02T14:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/bravo-trial-highlights-improved-detection-reduces-bladder-cancer-recurrence-from-urotoday 2024-11-02T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bravo-trial-highlights-improved-detection-reduces-bladder-cancer-recurrence-from-urotoday 2024-11-02T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/omega-3-supplements-show-benefit-in-apoe4-carriers-medpage-today 2024-11-02T14:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omega-3-supplements-show-benefit-in-apoe4-carriers-medpage-today 2024-11-02T14:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-really-cancer-more-concerns-about-accelerated-approval-metformin-and-cancer 2024-11-02T14:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-it-really-cancer-more-concerns-about-accelerated-approval-metformin-and-cancer 2024-11-02T14:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/compass-pathways-cuts-30-of-workforce-on-phase-3-trial-delays-yahoo-finance 2024-11-02T13:31:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/compass-pathways-cuts-30-of-workforce-on-phase-3-trial-delays-yahoo-finance 2024-11-02T13:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-mrk-pfe-abbv-nvs-lly-s-q3-earnings-in-focus 2024-11-02T13:30:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-mrk-pfe-abbv-nvs-lly-s-q3-earnings-in-focus 2024-11-02T13:30:40+00:00 weekly 0.7 https://trial.medpath.com/news/benefit-of-systemic-therapy-in-mindact-patients-with-small-er-positive-her2-negative 2024-11-02T13:25:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benefit-of-systemic-therapy-in-mindact-patients-with-small-er-positive-her2-negative 2024-11-02T13:25:31+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-globenewswire 2024-11-02T13:16:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-globenewswire 2024-11-02T13:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-medicalnewstoday 2024-11-02T13:12:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-medicalnewstoday 2024-11-02T13:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-02T13:10:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67 2024-11-02T13:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/nyu-langone-health-in-the-news-friday-november-1-2024 2024-11-02T12:52:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nyu-langone-health-in-the-news-friday-november-1-2024 2024-11-02T12:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/oikn-partners-with-us-companies-to-develop-command-center-concept-antara-news 2024-11-02T12:14:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oikn-partners-with-us-companies-to-develop-command-center-concept-antara-news 2024-11-02T12:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilars-month-in-review-october-2024-hcplive 2024-11-02T12:03:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilars-month-in-review-october-2024-hcplive 2024-11-02T12:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-rejects-sglt1-2-inhibitor-for-type-1-diabetes-medpage-today 2024-11-02T11:52:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-panel-rejects-sglt1-2-inhibitor-for-type-1-diabetes-medpage-today 2024-11-02T11:52:09+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-researchers-say-brain-stimulation-device-may-slow-symptoms-nbc-news 2024-11-02T11:34:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-researchers-say-brain-stimulation-device-may-slow-symptoms-nbc-news 2024-11-02T11:34:45+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-02T11:34:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-02T11:34:21+00:00 weekly 0.7 https://trial.medpath.com/news/vyn201-for-vitiligo-phase-1b-study-confirms-safety-dermatology-times 2024-11-02T11:16:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vyn201-for-vitiligo-phase-1b-study-confirms-safety-dermatology-times 2024-11-02T11:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-resource-center-opening-in-oak-cliff-cbs-news 2024-11-02T11:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alzheimer-s-resource-center-opening-in-oak-cliff-cbs-news 2024-11-02T11:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-evaluating-the-long-term-efficacy-and-peripheral-sensory-neuropathy-of-nature 2024-11-02T11:02:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-trial-evaluating-the-long-term-efficacy-and-peripheral-sensory-neuropathy-of-nature 2024-11-02T11:02:57+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-announces-results-from-phase-1b-2-trial-of-globenewswire 2024-11-02T09:31:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alx-oncology-announces-results-from-phase-1b-2-trial-of-globenewswire 2024-11-02T09:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-to-present-results-from-phase-3-ember-3-study-of-imlunestrant-an-oral-serd-and 2024-11-02T09:30:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-to-present-results-from-phase-3-ember-3-study-of-imlunestrant-an-oral-serd-and 2024-11-02T09:30:38+00:00 weekly 0.7 https://trial.medpath.com/news/essa-discontinues-phase-2-study-of-masofaniten-plus-enzalutamide-in-mcrpc-onclive 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-discontinues-phase-2-study-of-masofaniten-plus-enzalutamide-in-mcrpc-onclive 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/indirect-comparison-shows-superiority-of-cilta-cel-vs-soc-regimens-in-lenalidomide 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indirect-comparison-shows-superiority-of-cilta-cel-vs-soc-regimens-in-lenalidomide 2024-11-02T09:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-sought-for-avutometinib-plus-defactinib-in-recurrent-kras-low-grade-onclive 2024-11-02T09:25:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-sought-for-avutometinib-plus-defactinib-in-recurrent-kras-low-grade-onclive 2024-11-02T09:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/cms-grants-transitional-pass-through-payment-for-medtronic-symplicity-spyraltm-renal 2024-11-02T09:24:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cms-grants-transitional-pass-through-payment-for-medtronic-symplicity-spyraltm-renal 2024-11-02T09:24:41+00:00 weekly 0.7 https://trial.medpath.com/news/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-02T08:39:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-02T08:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/oncoinvent-announces-publication-of-18-month-safety-and-efficacy-data-from-the-phase-1 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncoinvent-announces-publication-of-18-month-safety-and-efficacy-data-from-the-phase-1 2024-11-02T08:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-to-host-conference-call-on-end-of-phase-2-fda-globenewswire 2024-11-02T08:02:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disc-medicine-to-host-conference-call-on-end-of-phase-2-fda-globenewswire 2024-11-02T08:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/infliximab-monotherapy-effective-as-combo-therapy-for-treating-inflammatory-bowel-disease 2024-11-02T07:52:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/infliximab-monotherapy-effective-as-combo-therapy-for-treating-inflammatory-bowel-disease 2024-11-02T07:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-submits-nda-for-ovarian-cancer-treatment-pharmaceutical-technology 2024-11-02T07:21:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-oncology-submits-nda-for-ovarian-cancer-treatment-pharmaceutical-technology 2024-11-02T07:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-1-2024 2024-11-02T07:05:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-november-1-2024 2024-11-02T07:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/less-frequent-elfabrio-dosing-for-fabry-disease-appears-to-be-safe-effective 2024-11-02T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/less-frequent-elfabrio-dosing-for-fabry-disease-appears-to-be-safe-effective 2024-11-02T06:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/blue-earth-therapeutics-reports-promising-phase-1-data-for-investigational-therapies 2024-11-02T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-earth-therapeutics-reports-promising-phase-1-data-for-investigational-therapies 2024-11-02T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/teva-presents-phase-3-solaris-trial-results-markets-insider 2024-11-02T06:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-presents-phase-3-solaris-trial-results-markets-insider 2024-11-02T06:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/predicting-deterioration-in-dengue-using-a-low-cost-wearable-for-continuous-clinical-monitoring 2024-11-02T05:21:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/predicting-deterioration-in-dengue-using-a-low-cost-wearable-for-continuous-clinical-monitoring 2024-11-02T05:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/bullous-pemphigoid-executive-insights-bullous-pemphigoid-executive-insights-us-eu5 2024-11-02T05:19:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bullous-pemphigoid-executive-insights-bullous-pemphigoid-executive-insights-us-eu5 2024-11-02T05:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/ai-algorithm-shows-promise-in-early-detection-of-rare-blood-disorder-pnh 2024-11-02T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-algorithm-shows-promise-in-early-detection-of-rare-blood-disorder-pnh 2024-11-02T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cap-002-to-treat-patients-with-developmental-and 2024-11-02T04:40:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-cap-002-to-treat-patients-with-developmental-and 2024-11-02T04:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-glp-1-drug-meets-goals-of-mash-trial-setting-stage-for-fda-ema-filings 2024-11-02T04:31:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-glp-1-drug-meets-goals-of-mash-trial-setting-stage-for-fda-ema-filings 2024-11-02T04:31:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-drug-for-schizophrenia-promises-few-side-effects-straight-arrow-news 2024-11-02T04:16:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-drug-for-schizophrenia-promises-few-side-effects-straight-arrow-news 2024-11-02T04:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/managing-amivantamab-s-complex-safety-profile-new-strategies-for-egfr-positive-nsclc-treatment 2024-11-02T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-amivantamab-s-complex-safety-profile-new-strategies-for-egfr-positive-nsclc-treatment 2024-11-02T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/rolling-nda-completed-for-avutometinib-combo-in-ovarian-cancer-subtype 2024-11-02T04:07:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rolling-nda-completed-for-avutometinib-combo-in-ovarian-cancer-subtype 2024-11-02T04:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-aol-com 2024-11-02T03:32:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-drug-for-ulcerative-colitis-also-effective-for-crohn-s-aol-com 2024-11-02T03:32:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-committee-votes-down-sotagliflozin-in-type-1-diabetes-and-ckd 2024-11-02T03:21:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advisory-committee-votes-down-sotagliflozin-in-type-1-diabetes-and-ckd 2024-11-02T03:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/rifaximin-reduced-overt-hepatic-encephalopathy-recurrence-over-lactulose 2024-11-02T03:18:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rifaximin-reduced-overt-hepatic-encephalopathy-recurrence-over-lactulose 2024-11-02T03:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/novel-immunotherapy-combo-shows-promise-in-melanoma-eurekalert 2024-11-02T02:42:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-immunotherapy-combo-shows-promise-in-melanoma-eurekalert 2024-11-02T02:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/dkn-01-with-tislelizumab-and-chemotherapy-in-advanced-gastric-or-gastroesophageal 2024-11-02T02:41:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dkn-01-with-tislelizumab-and-chemotherapy-in-advanced-gastric-or-gastroesophageal 2024-11-02T02:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/revisit-every-onclive-on-air-episode-from-october-2024 2024-11-02T02:18:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revisit-every-onclive-on-air-episode-from-october-2024 2024-11-02T02:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/inavolisib-regimen-continues-to-improve-survival-in-pik3ca-mutated-breast-cancer 2024-11-02T02:18:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inavolisib-regimen-continues-to-improve-survival-in-pik3ca-mutated-breast-cancer 2024-11-02T02:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-critical-care-gaps-and-economic-burden-for-metastatic-bone-disease-patients 2024-11-02T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-critical-care-gaps-and-economic-burden-for-metastatic-bone-disease-patients 2024-11-02T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-stock-tumbles-after-fda-adcom-votes-against-zynquista-again 2024-11-02T01:21:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-stock-tumbles-after-fda-adcom-votes-against-zynquista-again 2024-11-02T01:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough-hearing 2024-11-02T00:16:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough-hearing 2024-11-02T00:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-matched-targeted-therapy-improves-os-in-anaplastic-thyroid-cancer 2024-11-02T00:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atezolizumab-matched-targeted-therapy-improves-os-in-anaplastic-thyroid-cancer 2024-11-02T00:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-demonstrates-superiority-over-placebo-in-patients-with-metabolic-dysfunction 2024-11-01T23:53:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wegovy-demonstrates-superiority-over-placebo-in-patients-with-metabolic-dysfunction 2024-11-01T23:53:15+00:00 weekly 0.7 https://trial.medpath.com/news/recor-medical-announces-cms-grant-of-transitional-pass-through-tpt-payment-tradingview 2024-11-01T23:35:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recor-medical-announces-cms-grant-of-transitional-pass-through-tpt-payment-tradingview 2024-11-01T23:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-11-01T23:28:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-11-01T23:28:12+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-encouraging-results-in-her2-breast-cancer-with-brain-mets 2024-11-01T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-encouraging-results-in-her2-breast-cancer-with-brain-mets 2024-11-01T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/court-denies-jazz-s-challenge-of-avadel-s-orphan-drug-lumryz-sleep-review 2024-11-01T22:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/court-denies-jazz-s-challenge-of-avadel-s-orphan-drug-lumryz-sleep-review 2024-11-01T22:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-cancer-treatment-implantable-microparticles-deliver-dual-therapies 2024-11-01T22:35:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-cancer-treatment-implantable-microparticles-deliver-dual-therapies 2024-11-01T22:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-irhythm-s-second-510-k-in-response-to-warning-letter-medtech-dive 2024-11-01T22:29:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-irhythm-s-second-510-k-in-response-to-warning-letter-medtech-dive 2024-11-01T22:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/baili-tianheng-688506-rapid-promotion-of-innovation-pipeline-and-active-layout-of-yicai-global 2024-11-01T22:05:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/baili-tianheng-688506-rapid-promotion-of-innovation-pipeline-and-active-layout-of-yicai-global 2024-11-01T22:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-announces-results-from-phase-1b-2-trial-of-evorpacept-in-combination-with 2024-11-01T21:54:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alx-oncology-announces-results-from-phase-1b-2-trial-of-evorpacept-in-combination-with 2024-11-01T21:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/cmn-weekly-1-november-2024-your-weekly-crispr-medicine-news 2024-11-01T21:36:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cmn-weekly-1-november-2024-your-weekly-crispr-medicine-news 2024-11-01T21:36:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-sickle-cell-cure-exists-but-patients-need-more-than-just-gene-therapy-pharmavoice 2024-11-01T21:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-sickle-cell-cure-exists-but-patients-need-more-than-just-gene-therapy-pharmavoice 2024-11-01T21:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-formally-submits-bla-for-subcutaneous-autoinjector-of-lecanemab-neurologylive 2024-11-01T21:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-formally-submits-bla-for-subcutaneous-autoinjector-of-lecanemab-neurologylive 2024-11-01T21:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/ameluz-pdt-leads-to-target-lesion-clearance-in-superficial-basal-cell-carcinoma 2024-11-01T21:28:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ameluz-pdt-leads-to-target-lesion-clearance-in-superficial-basal-cell-carcinoma 2024-11-01T21:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ai-tool-that-flags-signs-of-heart-disease-in-chest-ct-scans 2024-11-01T21:23:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-ai-tool-that-flags-signs-of-heart-disease-in-chest-ct-scans 2024-11-01T21:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-wegovy-comparable-to-madrigal-s-rezdiffra-in-phase-iii-mash-trial-analysts 2024-11-01T21:10:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-s-wegovy-comparable-to-madrigal-s-rezdiffra-in-phase-iii-mash-trial-analysts 2024-11-01T21:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-inc-vir-q3-2024-earnings-call-highlights-st-gurufocus 2024-11-01T21:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-inc-vir-q3-2024-earnings-call-highlights-st-gurufocus 2024-11-01T21:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/does-an-additional-first-line-option-alter-approach-in-egfr-mutant-nsclc 2024-11-01T20:46:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/does-an-additional-first-line-option-alter-approach-in-egfr-mutant-nsclc 2024-11-01T20:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/glaucoma-drug-shows-promise-in-targeting-tau-buildup-inside-precision-medicine 2024-11-01T20:25:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glaucoma-drug-shows-promise-in-targeting-tau-buildup-inside-precision-medicine 2024-11-01T20:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/eliminate-trial-uuti-regimen-demonstrates-initial-tolerability-efficacy-urology-times 2024-11-01T20:20:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eliminate-trial-uuti-regimen-demonstrates-initial-tolerability-efficacy-urology-times 2024-11-01T20:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-rejects-lexicon-s-zynquista-for-type-1-diabetes-benzinga 2024-11-01T20:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-panel-rejects-lexicon-s-zynquista-for-type-1-diabetes-benzinga 2024-11-01T20:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/feliqs-receives-u-s-fda-fast-track-designation-for-flq-101-a-first-in-class-small-biospace 2024-11-01T20:00:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feliqs-receives-u-s-fda-fast-track-designation-for-flq-101-a-first-in-class-small-biospace 2024-11-01T20:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-compass-pathways-reports-q3-results-and-trial-updates-investing-com 2024-11-01T19:26:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-compass-pathways-reports-q3-results-and-trial-updates-investing-com 2024-11-01T19:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/nvo-reports-positive-phase-iii-trial-results-for-semaglutide-in-mash-treatment 2024-11-01T19:25:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvo-reports-positive-phase-iii-trial-results-for-semaglutide-in-mash-treatment 2024-11-01T19:25:17+00:00 weekly 0.7 https://trial.medpath.com/news/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-01T19:23:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-presents-latest-schizophrenia-treatment-research-including-phase-3-solaris-trial 2024-11-01T19:23:15+00:00 weekly 0.7 https://trial.medpath.com/news/casdatifan-demonstrates-durable-activity-in-metastatic-clear-cell-renal-cell-carcinoma 2024-11-01T19:18:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/casdatifan-demonstrates-durable-activity-in-metastatic-clear-cell-renal-cell-carcinoma 2024-11-01T19:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-october-2024-highlights-advancing-treatments-in-oncology 2024-11-01T19:17:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-october-2024-highlights-advancing-treatments-in-oncology 2024-11-01T19:17:33+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-drugs-approved-by-the-fda-in-october-2024-cure-today 2024-11-01T19:13:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncology-drugs-approved-by-the-fda-in-october-2024-cure-today 2024-11-01T19:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-a-s-semaglutide-2-4-mg-demonstrates-superior-globenewswire 2024-11-01T18:51:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-a-s-semaglutide-2-4-mg-demonstrates-superior-globenewswire 2024-11-01T18:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/two-topical-treatments-show-similar-benefits-for-photoaging-of-the-hands-news-medical 2024-11-01T18:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-topical-treatments-show-similar-benefits-for-photoaging-of-the-hands-news-medical 2024-11-01T18:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/stelara-may-be-effective-for-type-1-diabetes-in-adolescents 2024-11-01T18:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stelara-may-be-effective-for-type-1-diabetes-in-adolescents 2024-11-01T18:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-01T18:00:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-pharma-halts-phase-ii-study-of-masofaniten-in-prostate-cancer-treatment 2024-11-01T18:00:25+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-biologics-license-application-to-fda-for-subcutaneous 2024-11-01T17:53:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-biologics-license-application-to-fda-for-subcutaneous 2024-11-01T17:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-loses-fda-adcomm-vote-on-insulin-adjunct-for-patients-with-type-1-diabetes 2024-11-01T17:40:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-loses-fda-adcomm-vote-on-insulin-adjunct-for-patients-with-type-1-diabetes 2024-11-01T17:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trials-show-long-term-efficacy-of-cobenfy-treating-schizophrenia 2024-11-01T17:36:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-trials-show-long-term-efficacy-of-cobenfy-treating-schizophrenia 2024-11-01T17:36:59+00:00 weekly 0.7 https://trial.medpath.com/news/anti-tau-antibody-stumbles-in-phase-ii-alzheimer-trial-nature 2024-11-01T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-tau-antibody-stumbles-in-phase-ii-alzheimer-trial-nature 2024-11-01T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-weighs-up-alzheimer-s-drug-future-after-phase-ii-miss-and-roche-exit-scrip 2024-11-01T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-weighs-up-alzheimer-s-drug-future-after-phase-ii-miss-and-roche-exit-scrip 2024-11-01T17:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T17:05:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T17:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T17:05:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T17:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/tizona-s-ttx-080-colorectal-cancer-trial-expands-with-new-arms 2024-11-01T17:00:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tizona-s-ttx-080-colorectal-cancer-trial-expands-with-new-arms 2024-11-01T17:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-scemblix-for-newly-diagnosed-cml-patients-the-cancer-letter 2024-11-01T16:51:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-scemblix-for-newly-diagnosed-cml-patients-the-cancer-letter 2024-11-01T16:51:12+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-of-masofaniten-plus-enzalutamide-in-mcrpc-has-been-terminated 2024-11-01T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-of-masofaniten-plus-enzalutamide-in-mcrpc-has-been-terminated 2024-11-01T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/high-grade-cesium-results-continue-in-latest-drilling-phase-nationtalk 2024-11-01T16:44:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-grade-cesium-results-continue-in-latest-drilling-phase-nationtalk 2024-11-01T16:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/novo-with-new-results-to-seek-approval-for-obesity-drug-in-mash-biopharma-dive 2024-11-01T16:40:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-with-new-results-to-seek-approval-for-obesity-drug-in-mash-biopharma-dive 2024-11-01T16:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-red-tape-and-ethics-under-the-microscope-research-professional-news 2024-11-01T16:36:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-red-tape-and-ethics-under-the-microscope-research-professional-news 2024-11-01T16:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-reports-solid-progress-in-clinical-trials-raises-a-12-5-million-in 2024-11-01T16:33:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-reports-solid-progress-in-clinical-trials-raises-a-12-5-million-in 2024-11-01T16:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/predicting-pathological-response-of-neoadjuvant-conversion-therapy-for-jhc-dove-medical-press 2024-11-01T16:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/predicting-pathological-response-of-neoadjuvant-conversion-therapy-for-jhc-dove-medical-press 2024-11-01T16:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/powering-a-new-paradigm-for-pathology-danaher 2024-11-01T16:23:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/powering-a-new-paradigm-for-pathology-danaher 2024-11-01T16:23:51+00:00 weekly 0.7 https://trial.medpath.com/news/a-narrative-review-focusing-on-randomized-clinical-trials-rcts-of-vitamin-d-frontiers 2024-11-01T16:21:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-narrative-review-focusing-on-randomized-clinical-trials-rcts-of-vitamin-d-frontiers 2024-11-01T16:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-t1d-expresses-disappointment-in-fda-advisory-committee 2024-11-01T15:54:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-t1d-expresses-disappointment-in-fda-advisory-committee 2024-11-01T15:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/treatments-in-clinical-trials-for-small-cell-lung-cancer-healthline 2024-11-01T15:44:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatments-in-clinical-trials-for-small-cell-lung-cancer-healthline 2024-11-01T15:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/us-court-upholds-avadel-s-narcolepsy-drug-approval-amid-exclusivity-battle 2024-11-01T15:44:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-court-upholds-avadel-s-narcolepsy-drug-approval-amid-exclusivity-battle 2024-11-01T15:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/taking-on-acquired-resistance-in-egfr-mutant-nsclc-medpage-today 2024-11-01T15:35:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taking-on-acquired-resistance-in-egfr-mutant-nsclc-medpage-today 2024-11-01T15:35:14+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-non-small-cell-lung-cancer-medpage-today 2024-11-01T15:35:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/year-in-review-non-small-cell-lung-cancer-medpage-today 2024-11-01T15:35:12+00:00 weekly 0.7 https://trial.medpath.com/news/insomnia-breakthrough-handheld-device-in-development-may-soon-zap-away-sleepless-nights 2024-11-01T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insomnia-breakthrough-handheld-device-in-development-may-soon-zap-away-sleepless-nights 2024-11-01T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-globenewswire 2024-11-01T15:19:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-globenewswire 2024-11-01T15:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/inotuzumab-ozogamicin-with-low-intensity-chemotherapy-in-older-patients-with-cd22 2024-11-01T15:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inotuzumab-ozogamicin-with-low-intensity-chemotherapy-in-older-patients-with-cd22 2024-11-01T15:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/online-yoga-classes-can-ease-lower-back-pain 2024-11-01T15:11:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/online-yoga-classes-can-ease-lower-back-pain 2024-11-01T15:11:43+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-vir-biotechnology-advances-with-sanofi-deal-hepatitis-trials-investing-com 2024-11-01T15:11:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-vir-biotechnology-advances-with-sanofi-deal-hepatitis-trials-investing-com 2024-11-01T15:11:41+00:00 weekly 0.7 https://trial.medpath.com/news/chemo-should-be-tailored-to-decrease-neuropathy-in-black-patients-oncology-nursing-news 2024-11-01T15:08:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemo-should-be-tailored-to-decrease-neuropathy-in-black-patients-oncology-nursing-news 2024-11-01T15:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-virtual-yoga-for-chronic-low-back-pain-a-randomized-clinical-trial 2024-11-01T15:03:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-of-virtual-yoga-for-chronic-low-back-pain-a-randomized-clinical-trial 2024-11-01T15:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-agency-highlights-from-october-2024-drug-topics 2024-11-01T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-agency-highlights-from-october-2024-drug-topics 2024-11-01T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T14:41:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T14:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-battles-wall-street-uncertainty-madrigal-extends-fast-launch-of-mash-drug 2024-11-01T14:40:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-battles-wall-street-uncertainty-madrigal-extends-fast-launch-of-mash-drug 2024-11-01T14:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-is-the-new-hypertension-the-current-landscape-of-pharmacological-weight-loss 2024-11-01T14:31:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-is-the-new-hypertension-the-current-landscape-of-pharmacological-weight-loss 2024-11-01T14:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/video-experts-consider-endpoints-for-clinical-trials-in-geographic-atrophy-healio 2024-11-01T14:31:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/video-experts-consider-endpoints-for-clinical-trials-in-geographic-atrophy-healio 2024-11-01T14:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/uk-approves-cstone-s-sugemalimab-for-non-small-cell-lung-cancer-treatment 2024-11-01T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-approves-cstone-s-sugemalimab-for-non-small-cell-lung-cancer-treatment 2024-11-01T14:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-01T14:08:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-01T14:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-biogen-eye-2025-approval-for-leqembi-autoinjector-pharmaphorum 2024-11-01T14:07:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-biogen-eye-2025-approval-for-leqembi-autoinjector-pharmaphorum 2024-11-01T14:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/hansoh-pharmaceutical-group-company-limited-announces-the-nmpa-has-granted 2024-11-01T14:02:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hansoh-pharmaceutical-group-company-limited-announces-the-nmpa-has-granted 2024-11-01T14:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/overcollection-of-data-adds-months-to-clinical-trials-and-reduces-roi-finds-new-phesi-analysis 2024-11-01T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/overcollection-of-data-adds-months-to-clinical-trials-and-reduces-roi-finds-new-phesi-analysis 2024-11-01T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/pl-developments-receives-fda-approval-for-over-the-counter-omeprazole 2024-11-01T13:36:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pl-developments-receives-fda-approval-for-over-the-counter-omeprazole 2024-11-01T13:36:37+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-insmed-reports-strong-q3-growth-eyes-brensocatib-launch-investing-com 2024-11-01T13:31:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-insmed-reports-strong-q3-growth-eyes-brensocatib-launch-investing-com 2024-11-01T13:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/with-new-wegovy-data-in-hand-novo-nordisk-will-file-for-approval-in-mash-stat-news 2024-11-01T13:24:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-new-wegovy-data-in-hand-novo-nordisk-will-file-for-approval-in-mash-stat-news 2024-11-01T13:24:12+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-can-new-blood-tests-help-diagnose-the-disease-early-medicalnewstoday 2024-11-01T13:07:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-can-new-blood-tests-help-diagnose-the-disease-early-medicalnewstoday 2024-11-01T13:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/readout-newsletter-madrigal-eli-lilly-compass-pathways-latest-stat-news 2024-11-01T13:03:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/readout-newsletter-madrigal-eli-lilly-compass-pathways-latest-stat-news 2024-11-01T13:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/break-through-cancer-announces-first-patient-enrolled-in-phase-2-trial-targeting-residual 2024-11-01T12:58:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/break-through-cancer-announces-first-patient-enrolled-in-phase-2-trial-targeting-residual 2024-11-01T12:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:43:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:43:03+00:00 weekly 0.7 https://trial.medpath.com/news/disparities-in-ibs-clinical-trial-participation-suggest-healthcare-research-inequities 2024-11-01T12:40:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disparities-in-ibs-clinical-trial-participation-suggest-healthcare-research-inequities 2024-11-01T12:40:51+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-concludes-enrolment-for-omny-af-trial-pilot-phase 2024-11-01T12:38:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-medtech-concludes-enrolment-for-omny-af-trial-pilot-phase 2024-11-01T12:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/sotagliflozin-setback-cautionary-fda-adcomm-vote-reflects-continued-concern-for 2024-11-01T12:38:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotagliflozin-setback-cautionary-fda-adcomm-vote-reflects-continued-concern-for 2024-11-01T12:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/dijon-biotech-company-inventiva-raises-348-million-to-complete-its-phase-iii-born2invest 2024-11-01T12:35:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dijon-biotech-company-inventiva-raises-348-million-to-complete-its-phase-iii-born2invest 2024-11-01T12:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-s-relacorilant-gradient-trial-misses-primary-endpoint 2024-11-01T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-s-relacorilant-gradient-trial-misses-primary-endpoint 2024-11-01T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-weighs-whether-speedy-approval-path-is-open-for-latest-alzheimer-s-drug 2024-11-01T12:27:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-weighs-whether-speedy-approval-path-is-open-for-latest-alzheimer-s-drug 2024-11-01T12:27:13+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-granted-fda-accelerated-approval-in-newly-diagnosed-cml-pmlive 2024-11-01T12:26:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-granted-fda-accelerated-approval-in-newly-diagnosed-cml-pmlive 2024-11-01T12:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/dermavant-reports-positive-long-term-results-for-vtama-cream-in-atopic-dermatitis-pmlive 2024-11-01T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermavant-reports-positive-long-term-results-for-vtama-cream-in-atopic-dermatitis-pmlive 2024-11-01T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-01T12:14:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-initiation-of-the-registration-enabling-reframe-p1-trial-with 2024-11-01T12:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:09:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envoy-medical-receives-fda-approval-to-initiate-pivotal-clinical-study-for-breakthrough 2024-11-01T12:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/mechanisms-of-acquired-resistance-in-first-line-treatment-amivantamab-plus-lazertinib 2024-11-01T12:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mechanisms-of-acquired-resistance-in-first-line-treatment-amivantamab-plus-lazertinib 2024-11-01T12:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:00:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biofrontera-stock-climbs-as-drug-device-succeeds-in-phase-iii-skin-cancer-trial 2024-11-01T12:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/seltorexant-shows-promise-as-first-in-class-treatment-for-depression-with-insomnia-in-phase-iii-trial 2024-11-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seltorexant-shows-promise-as-first-in-class-treatment-for-depression-with-insomnia-in-phase-iii-trial 2024-11-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-in-combination-with-keytruda 2024-11-01T11:44:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-in-combination-with-keytruda 2024-11-01T11:44:59+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-galapagos-reports-solid-q3-progress-eyes-ind-studies-investing-com 2024-11-01T11:31:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-galapagos-reports-solid-q3-progress-eyes-ind-studies-investing-com 2024-11-01T11:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T11:30:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-phase-iii-clinical-trial-application-for-first-line-treatment-of-extensive-disease-small-cell 2024-11-01T11:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-treatment-of-arteriovenous-malformation-shine-news-shanghai-daily 2024-11-01T11:27:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-treatment-of-arteriovenous-malformation-shine-news-shanghai-daily 2024-11-01T11:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-raising-ps8-5m-to-fund-us-clinical-trial-sharecast-com 2024-11-01T11:26:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ondine-raising-ps8-5m-to-fund-us-clinical-trial-sharecast-com 2024-11-01T11:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-globenewswire 2024-11-01T11:18:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-globenewswire 2024-11-01T11:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/aim-vaccine-co-ltd-announces-13-valent-pneumonia-conjugate-vaccine-marketscreener 2024-11-01T11:16:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aim-vaccine-co-ltd-announces-13-valent-pneumonia-conjugate-vaccine-marketscreener 2024-11-01T11:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-morningstar 2024-11-01T11:12:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-morningstar 2024-11-01T11:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/diadem-unveils-novel-findings-on-early-alzheimer-s-disease-detection-using-p53-specific-antibody-at-ctad-2024 2024-11-01T11:11:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diadem-unveils-novel-findings-on-early-alzheimer-s-disease-detection-using-p53-specific-antibody-at-ctad-2024 2024-11-01T11:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of 2024-11-01T11:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of 2024-11-01T11:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-revised-implementing-regulations-of-the-human-research-act-swissmedic 2024-11-01T10:39:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-revised-implementing-regulations-of-the-human-research-act-swissmedic 2024-11-01T10:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-s-type-1-diabetes-drug-voted-down-by-fda-adcomm-pharmaphorum 2024-11-01T10:27:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-s-type-1-diabetes-drug-voted-down-by-fda-adcomm-pharmaphorum 2024-11-01T10:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/no-evidence-adults-with-autism-are-more-vulnerable-to-criminals-study-finds 2024-11-01T10:11:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-evidence-adults-with-autism-are-more-vulnerable-to-criminals-study-finds 2024-11-01T10:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-could-help-ease-knee-arthritis-pain 2024-11-01T10:11:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-could-help-ease-knee-arthritis-pain 2024-11-01T10:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T10:07:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-hympavzi-for-hemophilia-a-and-b-treatment-technology-networks 2024-11-01T10:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/hansoh-pharma-s-breakthrough-in-cancer-drug-development-tipranks-com 2024-11-01T09:37:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hansoh-pharma-s-breakthrough-in-cancer-drug-development-tipranks-com 2024-11-01T09:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/8th-summit-advances-antigen-specific-immune-tolerance-therapies-for-autoimmune-diseases 2024-11-01T09:25:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/8th-summit-advances-antigen-specific-immune-tolerance-therapies-for-autoimmune-diseases 2024-11-01T09:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-adcomm-votes-against-lexicon-type-1-diabetes-and-ckd-drug-endpoints-news 2024-11-01T09:11:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-adcomm-votes-against-lexicon-type-1-diabetes-and-ckd-drug-endpoints-news 2024-11-01T09:11:03+00:00 weekly 0.7 https://trial.medpath.com/news/reductions-in-substance-use-as-outcome-targets-for-treatment-development 2024-11-01T08:51:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reductions-in-substance-use-as-outcome-targets-for-treatment-development 2024-11-01T08:51:18+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-biogen-eye-2025-approval-for-subcutaneous-leqembi-pharmaphorum 2024-11-01T08:02:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-biogen-eye-2025-approval-for-subcutaneous-leqembi-pharmaphorum 2024-11-01T08:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/new-trials-for-potential-flu-and-norovirus-vaccines-dartmouth-today-co-uk 2024-11-01T08:00:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trials-for-potential-flu-and-norovirus-vaccines-dartmouth-today-co-uk 2024-11-01T08:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/blue-therapeutics-gets-financing-to-push-radiotherapies-european-biotechnology 2024-11-01T07:48:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-therapeutics-gets-financing-to-push-radiotherapies-european-biotechnology 2024-11-01T07:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/recruiting-and-retaining-healthcare-workers-in-scotland-to-a-longitudinal-covid-19-study 2024-11-01T07:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recruiting-and-retaining-healthcare-workers-in-scotland-to-a-longitudinal-covid-19-study 2024-11-01T07:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/incorporating-external-controls-in-the-design-of-randomized-clinical-trials-a-case-study-in-solid-tumors 2024-11-01T07:29:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incorporating-external-controls-in-the-design-of-randomized-clinical-trials-a-case-study-in-solid-tumors 2024-11-01T07:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-biospace 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-biospace 2024-11-01T07:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-reports-third-quarter-2024-financial-and-operating-results-biospace 2024-11-01T07:21:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-reports-third-quarter-2024-financial-and-operating-results-biospace 2024-11-01T07:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/h-lundbeck-a-s-announces-positive-results-from-phase-iii-pivotal-trial-of-vyepti 2024-11-01T07:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/h-lundbeck-a-s-announces-positive-results-from-phase-iii-pivotal-trial-of-vyepti 2024-11-01T07:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/opdivo-and-yervoy-may-improve-survival-for-resected-stage-3-4-melanoma-cure-today 2024-11-01T07:12:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opdivo-and-yervoy-may-improve-survival-for-resected-stage-3-4-melanoma-cure-today 2024-11-01T07:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-pharmaceuticals-inc-alny-q3-2024-earnings-highlights 2024-11-01T07:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-pharmaceuticals-inc-alny-q3-2024-earnings-highlights 2024-11-01T07:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/agios-pharmaceuticals-inc-agio-q3-2024-earnings-call-highlights-strong-cash-position-and 2024-11-01T07:04:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-pharmaceuticals-inc-agio-q3-2024-earnings-call-highlights-strong-cash-position-and 2024-11-01T07:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/rosella-trial-of-relacorilant-targets-stress-response-to-overcome-chemoresistance-in 2024-11-01T06:59:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rosella-trial-of-relacorilant-targets-stress-response-to-overcome-chemoresistance-in 2024-11-01T06:59:03+00:00 weekly 0.7 https://trial.medpath.com/news/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-to-ethics-and-regulation 2024-11-01T06:03:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-to-ethics-and-regulation 2024-11-01T06:03:32+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-acn-newswire 2024-11-01T05:56:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-acn-newswire 2024-11-01T05:56:35+00:00 weekly 0.7 https://trial.medpath.com/news/dr-kotecha-on-the-fda-approval-of-optune-lua-in-metastatic-nsclc-onclive 2024-11-01T05:47:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-kotecha-on-the-fda-approval-of-optune-lua-in-metastatic-nsclc-onclive 2024-11-01T05:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T05:43:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T05:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimer-s-disease-in-phase-2a 2024-11-01T05:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimer-s-disease-in-phase-2a 2024-11-01T05:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/critical-drug-shortages-persist-in-us-adhd-medications-chemotherapy-drugs-and-insulin-among-most-affected 2024-11-01T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/critical-drug-shortages-persist-in-us-adhd-medications-chemotherapy-drugs-and-insulin-among-most-affected 2024-11-01T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-biospace 2024-11-01T04:48:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-biospace 2024-11-01T04:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/study-cholinesterase-inhibitors-show-promise-for-lewy-body-dementia-being-patient 2024-11-01T04:38:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-cholinesterase-inhibitors-show-promise-for-lewy-body-dementia-being-patient 2024-11-01T04:38:43+00:00 weekly 0.7 https://trial.medpath.com/news/handok-s-rare-blood-disorder-treatment-empaveli-wins-insurance-coverage-kbr 2024-11-01T04:26:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/handok-s-rare-blood-disorder-treatment-empaveli-wins-insurance-coverage-kbr 2024-11-01T04:26:27+00:00 weekly 0.7 https://trial.medpath.com/news/dimerix-collaborates-with-neptune-for-trial-recruitment-markets-insider 2024-11-01T02:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dimerix-collaborates-with-neptune-for-trial-recruitment-markets-insider 2024-11-01T02:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T02:46:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination-as 2024-11-01T02:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/first-fda-approved-treatment-to-delay-type-1-diabetes-ucsf-diabetes-center-57b993 2024-11-01T02:36:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-fda-approved-treatment-to-delay-type-1-diabetes-ucsf-diabetes-center-57b993 2024-11-01T02:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T02:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquistatm-sotagliflozin-as 2024-11-01T02:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-exactech-porous-3d-tibial-implant-for-knee-replacement-massdevice 2024-11-01T02:22:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-exactech-porous-3d-tibial-implant-for-knee-replacement-massdevice 2024-11-01T02:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/glaucoma-drug-may-pave-unexpected-road-to-a-dementia-cure-study-finds 2024-11-01T02:06:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glaucoma-drug-may-pave-unexpected-road-to-a-dementia-cure-study-finds 2024-11-01T02:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-01T01:52:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-01T01:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-approved-treatment-for-hyperhidrosis-slucare-health-watch-826020 2024-11-01T01:25:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-approved-treatment-for-hyperhidrosis-slucare-health-watch-826020 2024-11-01T01:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined 2024-11-01T01:17:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined 2024-11-01T01:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/prolong-pharmaceuticals-gains-us-fda-fast-track-designation-for-novel-stroke-therapy 2024-11-01T00:41:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prolong-pharmaceuticals-gains-us-fda-fast-track-designation-for-novel-stroke-therapy 2024-11-01T00:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-whets-investors-appetites-for-maritide-obesity-data-by-end-of-year-biospace 2024-11-01T00:38:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-whets-investors-appetites-for-maritide-obesity-data-by-end-of-year-biospace 2024-11-01T00:38:59+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:17:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:03:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-submission-to-us-fda-for-leqembi-r-lecanemab-irmb-biologics 2024-11-01T00:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-elevar-s-resubmitted-rivoceranib-and-camrelizumab 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-elevar-s-resubmitted-rivoceranib-and-camrelizumab 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tct-2024-one-year-data-from-sirona-trial-show-similar-results-for 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tct-2024-one-year-data-from-sirona-trial-show-similar-results-for 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/primary-day-28-analysis-of-a-phase-2-3-open-label-study 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primary-day-28-analysis-of-a-phase-2-3-open-label-study 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunochemotherapy-shows-promise-for-borderline-resectable-esophageal-cancer-conversion-surgery 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunochemotherapy-shows-promise-for-borderline-resectable-esophageal-cancer-conversion-surgery 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elexacaftor-tezacaftor-ivacaftor-shows-promise-for-cystic-fibrosis-patients-without-f508del-cftr-variant 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elexacaftor-tezacaftor-ivacaftor-shows-promise-for-cystic-fibrosis-patients-without-f508del-cftr-variant 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-evaluates-recurrence-of-disease-activity-after-ocrelizumab-discontinuation-in-ms-patients 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-evaluates-recurrence-of-disease-activity-after-ocrelizumab-discontinuation-in-ms-patients 2024-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:51:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:51:49+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:47:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-completes-rolling-bla-submission-for-subcutaneous-maintenance-dosing-of-leqembi 2024-10-31T23:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-pharmaceuticals-gets-negative-fda-panel-vote-for-zynquista-update 2024-10-31T23:34:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-pharmaceuticals-gets-negative-fda-panel-vote-for-zynquista-update 2024-10-31T23:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate 2024-10-31T23:18:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate 2024-10-31T23:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-globenewswire 2024-10-31T22:59:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-announces-outcome-of-fda-advisory-committee-for-globenewswire 2024-10-31T22:59:03+00:00 weekly 0.7 https://trial.medpath.com/news/scs-aua-2024-indications-and-outcomes-for-radiation-therapy-in-renal-masses 2024-10-31T22:41:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scs-aua-2024-indications-and-outcomes-for-radiation-therapy-in-renal-masses 2024-10-31T22:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/multicenter-group-compares-real-world-mesothelioma-outcomes-to-clinical-study 2024-10-31T22:33:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multicenter-group-compares-real-world-mesothelioma-outcomes-to-clinical-study 2024-10-31T22:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/edwards-medtronic-and-inari-share-trial-data-at-tct-conference-medtech-dive 2024-10-31T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edwards-medtronic-and-inari-share-trial-data-at-tct-conference-medtech-dive 2024-10-31T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-300-shows-encouraging-safety-efficacy-in-fgfr3-metastatic-urothelial-carcinoma 2024-10-31T22:04:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-300-shows-encouraging-safety-efficacy-in-fgfr3-metastatic-urothelial-carcinoma 2024-10-31T22:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/sugemalimab-plus-chemotherapy-earns-uk-approval-in-first-line-metastatic-nsclc 2024-10-31T21:49:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sugemalimab-plus-chemotherapy-earns-uk-approval-in-first-line-metastatic-nsclc 2024-10-31T21:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T21:47:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T21:47:45+00:00 weekly 0.7 https://trial.medpath.com/news/the-changing-landscape-of-ph-positive-all-targeted-oncology 2024-10-31T21:47:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-changing-landscape-of-ph-positive-all-targeted-oncology 2024-10-31T21:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-antibody-against-alzheimer-s-looks-the-best-yet-barron-s 2024-10-31T21:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-antibody-against-alzheimer-s-looks-the-best-yet-barron-s 2024-10-31T21:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/clindamycin-and-bacterial-load-reduction-as-prophylaxis-for-surgical-site-infection-racgp 2024-10-31T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clindamycin-and-bacterial-load-reduction-as-prophylaxis-for-surgical-site-infection-racgp 2024-10-31T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/dermatology-times-october-2024-recap 2024-10-31T21:15:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermatology-times-october-2024-recap 2024-10-31T21:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquista-sotagliflozin-as-an-adjunct-to-insulin-therapy-for-glycemic-control-in-adults-with-type-1-diabetes-and-chronic-kidney-disease 2024-10-31T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquista-sotagliflozin-as-an-adjunct-to-insulin-therapy-for-glycemic-control-in-adults-with-type-1-diabetes-and-chronic-kidney-disease 2024-10-31T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T21:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T21:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-pabon-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-pabon-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/dr-foss-on-the-fda-approval-of-denileukin-diftitox-for-ctcl-onclive 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-foss-on-the-fda-approval-of-denileukin-diftitox-for-ctcl-onclive 2024-10-31T20:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-resubmits-bla-to-fda-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-10-31T20:48:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abeona-therapeutics-resubmits-bla-to-fda-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-10-31T20:48:42+00:00 weekly 0.7 https://trial.medpath.com/news/jefferies-raises-kymera-therapeutics-target-to-59-on-immunology-and-inflammation-focus 2024-10-31T20:35:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jefferies-raises-kymera-therapeutics-target-to-59-on-immunology-and-inflammation-focus 2024-10-31T20:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-sec-10-q-report-tradingview 2024-10-31T20:25:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-sec-10-q-report-tradingview 2024-10-31T20:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-continues-to-fill-its-malaria-pipeline-with-a-long-half-life-iv-compound-for-severe-malaria 2024-10-31T20:16:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-continues-to-fill-its-malaria-pipeline-with-a-long-half-life-iv-compound-for-severe-malaria 2024-10-31T20:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-announces-third-quarter-2024-results-and-provides-business-update 2024-10-31T20:11:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-announces-third-quarter-2024-results-and-provides-business-update 2024-10-31T20:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-10-31T20:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/inavolisib-regimen-approval-opens-the-door-for-triplet-therapies-in-hr-her2-breast-cancer 2024-10-31T20:08:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inavolisib-regimen-approval-opens-the-door-for-triplet-therapies-in-hr-her2-breast-cancer 2024-10-31T20:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-wainzua-gains-another-approval-in-england-and-wales-pharmtech 2024-10-31T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-wainzua-gains-another-approval-in-england-and-wales-pharmtech 2024-10-31T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/iovance-biotherapeutics-to-host-third-quarter-and-globenewswire 2024-10-31T20:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iovance-biotherapeutics-to-host-third-quarter-and-globenewswire 2024-10-31T20:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-data-presented-at-ctad-on-early-initiation-and-long-term-treatment-suggest 2024-10-31T19:50:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-data-presented-at-ctad-on-early-initiation-and-long-term-treatment-suggest 2024-10-31T19:50:58+00:00 weekly 0.7 https://trial.medpath.com/news/st-luke-s-surgeon-honored-for-research-work-lvb-lehigh-valley-business 2024-10-31T19:50:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/st-luke-s-surgeon-honored-for-research-work-lvb-lehigh-valley-business 2024-10-31T19:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/roche-announces-phase-iii-inavo120-results-were-published-markets-insider 2024-10-31T19:45:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-announces-phase-iii-inavo120-results-were-published-markets-insider 2024-10-31T19:45:26+00:00 weekly 0.7 https://trial.medpath.com/news/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T19:39:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T19:39:17+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-earns-higher-revenues-in-q3-2024-puts-rare-diseases-in-the-spotlight 2024-10-31T19:35:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-earns-higher-revenues-in-q3-2024-puts-rare-diseases-in-the-spotlight 2024-10-31T19:35:29+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/a-promising-schizophrenia-drug-showed-mixed-results-what-does-that-mean-for-patients 2024-10-31T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-promising-schizophrenia-drug-showed-mixed-results-what-does-that-mean-for-patients 2024-10-31T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/starget-pharma-secures-5-1m-for-ai-powered-targeted-radiotherapy-for-cancer 2024-10-31T19:16:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/starget-pharma-secures-5-1m-for-ai-powered-targeted-radiotherapy-for-cancer 2024-10-31T19:16:53+00:00 weekly 0.7 https://trial.medpath.com/news/standout-breast-cancer-trial-outcomes-for-roche-small-molecule-therapy 2024-10-31T19:13:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/standout-breast-cancer-trial-outcomes-for-roche-small-molecule-therapy 2024-10-31T19:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:03:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:01:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-mcguff-pharmaceuticals-facility-in-santa-ana-ca-contract-pharma 2024-10-31T19:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-pd-l1-in-patients-with-non-small-cell-lung-cancer-receiving-neoadjuvant-immune 2024-10-31T18:37:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-role-of-pd-l1-in-patients-with-non-small-cell-lung-cancer-receiving-neoadjuvant-immune 2024-10-31T18:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-3-data-suggest-benefits-of-early-lecanemab-initiation-on-alzheimer-disease 2024-10-31T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-phase-3-data-suggest-benefits-of-early-lecanemab-initiation-on-alzheimer-disease 2024-10-31T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/power-metals-high-grade-cesium-results-continue-in-latest-drilling-phase-junior-mining-network 2024-10-31T18:05:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/power-metals-high-grade-cesium-results-continue-in-latest-drilling-phase-junior-mining-network 2024-10-31T18:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-test-predicts-survival-benefit-from-docetaxel-in-prostate-cancer-oncology-times 2024-10-31T17:46:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetic-test-predicts-survival-benefit-from-docetaxel-in-prostate-cancer-oncology-times 2024-10-31T17:46:16+00:00 weekly 0.7 https://trial.medpath.com/news/ninth-circuit-confirms-certain-stem-cell-products-require-fda-premarket-approval 2024-10-31T17:40:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ninth-circuit-confirms-certain-stem-cell-products-require-fda-premarket-approval 2024-10-31T17:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/oral-and017-granted-orphan-drug-status-for-scd-sickle-cell-disease-news 2024-10-31T17:31:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-and017-granted-orphan-drug-status-for-scd-sickle-cell-disease-news 2024-10-31T17:31:19+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-shows-thrombectomy-does-not-improve-outcomes-for-patients-with-large-strokes 2024-10-31T17:26:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-shows-thrombectomy-does-not-improve-outcomes-for-patients-with-large-strokes 2024-10-31T17:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/participant-motivations-key-to-success-in-clinical-trials-dermatology-times 2024-10-31T17:10:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/participant-motivations-key-to-success-in-clinical-trials-dermatology-times 2024-10-31T17:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/jancelewicz-co-principal-investigator-on-11-4-million-clinical-trial-grant-to-study 2024-10-31T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jancelewicz-co-principal-investigator-on-11-4-million-clinical-trial-grant-to-study 2024-10-31T17:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/defining-the-characteristics-of-breakthrough-invasive-fungal-infections-in-hematologic-disorders 2024-10-31T16:56:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/defining-the-characteristics-of-breakthrough-invasive-fungal-infections-in-hematologic-disorders 2024-10-31T16:56:24+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-10-31T16:47:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-10-31T16:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T16:46:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T16:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fast-tracks-asciminib-for-new-chronic-leukemia-patients-webmd 2024-10-31T16:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-fast-tracks-asciminib-for-new-chronic-leukemia-patients-webmd 2024-10-31T16:46:39+00:00 weekly 0.7